Esperion Therapeutics, Inc. (ESPR)
USD 1.09
(10.77%)
USD 1.09
(10.77%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -155.56 Million USD | 13.34% |
| 2022 | -179.5 Million USD | 20.83% |
| 2021 | -226.73 Million USD | -86.77% |
| 2020 | -121.39 Million USD | -30.39% |
| 2019 | -93.1 Million USD | 54.49% |
| 2018 | -204.58 Million USD | -21.07% |
| 2017 | -168.98 Million USD | -121.91% |
| 2016 | -76.15 Million USD | -52.18% |
| 2015 | -50.04 Million USD | -38.14% |
| 2014 | -36.22 Million USD | -59.17% |
| 2013 | -22.75 Million USD | -123.04% |
| 2012 | -10.2 Million USD | -0.39% |
| 2011 | -10.16 Million USD | 0.0% |
| 2002 | -27.94 Million USD | -2.31% |
| 2001 | -27.31 Million USD | 0.93% |
| 2000 | -27.57 Million USD | -122.92% |
| 1999 | -12.36 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 2.57 Million USD | -96.43% |
| 2024 Q1 | 72.26 Million USD | 270.58% |
| 2023 FY | -155.56 Million USD | 13.34% |
| 2023 Q1 | -48.6 Million USD | -14.33% |
| 2023 Q4 | -42.36 Million USD | -53.88% |
| 2023 Q2 | -37.05 Million USD | 23.76% |
| 2023 Q3 | -27.53 Million USD | 25.7% |
| 2022 FY | -179.5 Million USD | 20.83% |
| 2022 Q4 | -42.51 Million USD | -2.14% |
| 2022 Q3 | -41.62 Million USD | 20.53% |
| 2022 Q2 | -52.37 Million USD | -21.84% |
| 2022 Q1 | -42.98 Million USD | 22.72% |
| 2021 Q4 | -55.62 Million USD | 0.21% |
| 2021 Q3 | -55.74 Million USD | -71.35% |
| 2021 Q2 | -32.53 Million USD | 60.72% |
| 2021 Q1 | -82.82 Million USD | 13.34% |
| 2021 FY | -226.73 Million USD | -86.77% |
| 2020 Q1 | -74.44 Million USD | -26.26% |
| 2020 FY | -121.39 Million USD | -30.39% |
| 2020 Q3 | -80.55 Million USD | -162.36% |
| 2020 Q4 | -95.56 Million USD | -18.64% |
| 2020 Q2 | 129.17 Million USD | 273.51% |
| 2019 Q4 | -58.96 Million USD | 10.35% |
| 2019 Q1 | 86.92 Million USD | 243.33% |
| 2019 Q2 | -55.29 Million USD | -163.61% |
| 2019 Q3 | -65.76 Million USD | -18.93% |
| 2019 FY | -93.1 Million USD | 54.49% |
| 2018 Q2 | -46.48 Million USD | 0.88% |
| 2018 FY | -204.58 Million USD | -21.07% |
| 2018 Q1 | -46.89 Million USD | -21.19% |
| 2018 Q4 | -60.64 Million USD | -19.95% |
| 2018 Q3 | -50.56 Million USD | -8.78% |
| 2017 Q1 | -40.88 Million USD | -39.62% |
| 2017 FY | -168.98 Million USD | -121.91% |
| 2017 Q4 | -38.69 Million USD | 15.39% |
| 2017 Q3 | -45.73 Million USD | -4.76% |
| 2017 Q2 | -43.66 Million USD | -6.78% |
| 2016 Q2 | -14.33 Million USD | 3.31% |
| 2016 FY | -76.15 Million USD | -52.18% |
| 2016 Q4 | -29.28 Million USD | -65.34% |
| 2016 Q3 | -17.71 Million USD | -23.59% |
| 2016 Q1 | -14.82 Million USD | -12.0% |
| 2015 Q3 | -12.91 Million USD | -3.67% |
| 2015 FY | -50.04 Million USD | -38.14% |
| 2015 Q2 | -12.46 Million USD | -9.08% |
| 2015 Q4 | -13.23 Million USD | -2.44% |
| 2015 Q1 | -11.42 Million USD | -21.8% |
| 2014 Q4 | -9.38 Million USD | 3.3% |
| 2014 Q1 | -7.89 Million USD | 18.96% |
| 2014 Q3 | -9.7 Million USD | -4.82% |
| 2014 FY | -36.22 Million USD | -59.17% |
| 2014 Q2 | -9.25 Million USD | -17.29% |
| 2013 FY | -22.75 Million USD | -123.04% |
| 2013 Q1 | -3.34 Million USD | -54.81% |
| 2013 Q2 | -4.27 Million USD | -27.75% |
| 2013 Q3 | -5.4 Million USD | -26.57% |
| 2013 Q4 | -9.73 Million USD | -80.07% |
| 2012 Q2 | -2.86 Million USD | -30.8% |
| 2012 Q4 | -2.16 Million USD | 27.76% |
| 2012 Q3 | -2.99 Million USD | -4.41% |
| 2012 Q1 | -2.18 Million USD | 0.0% |
| 2012 FY | -10.2 Million USD | -0.39% |
| 2011 FY | -10.16 Million USD | 0.0% |
| 2003 Q3 | -6.22 Million USD | 20.58% |
| 2003 Q2 | -7.83 Million USD | -10.5% |
| 2003 Q1 | -7.08 Million USD | -14.39% |
| 2002 Q2 | -7.3 Million USD | 0.6% |
| 2002 FY | -27.94 Million USD | -2.31% |
| 2002 Q3 | -7.09 Million USD | 2.92% |
| 2002 Q4 | -6.19 Million USD | 12.63% |
| 2002 Q1 | -7.35 Million USD | -10.51% |
| 2001 Q2 | -8.93 Million USD | 1.37% |
| 2001 FY | -27.31 Million USD | 0.93% |
| 2001 Q4 | -6.65 Million USD | -2.21% |
| 2001 Q3 | -6.5 Million USD | 27.19% |
| 2001 Q1 | -9.06 Million USD | -57.64% |
| 2000 Q2 | -7.68 Million USD | -30.63% |
| 2000 Q1 | -5.87 Million USD | 0.0% |
| 2000 Q3 | -8.26 Million USD | -7.6% |
| 2000 Q4 | -5.74 Million USD | 30.45% |
| 2000 FY | -27.57 Million USD | -122.92% |
| 1999 FY | -12.36 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 431.189% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -930.082% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 193.173% |
| Cosmos Health Inc. | -21.83 Million USD | -612.571% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -675.873% |
| Cronos Group Inc. | -81.37 Million USD | -91.167% |
| Incannex Healthcare Limited | -30.04 Million USD | -417.836% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -297.321% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 1767.163% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -3184.188% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -3150.852% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -3150.852% |
| SCYNEXIS, Inc. | 72.66 Million USD | 314.071% |
| Safety Shot Inc | -12.18 Million USD | -1176.765% |
| Theratechnologies Inc. | -10.62 Million USD | -1363.847% |
| Alpha Teknova, Inc. | -35.56 Million USD | -337.429% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -4310.915% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 277.431% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -3209.147% |
| Dynavax Technologies Corporation | -37.02 Million USD | -320.123% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 174.419% |
| Radius Health, Inc. | -3.92 Million USD | -3863.389% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -6084.874% |
| Alvotech | -354.86 Million USD | 56.162% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 2.396% |
| SIGA Technologies, Inc. | 83.62 Million USD | 286.033% |
| Shineco, Inc. | -17.06 Million USD | -811.544% |
| Silver Spike Investment Corp. | 7.34 Million USD | 2219.355% |
| Journey Medical Corporation | -2.07 Million USD | -7404.245% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -1042.387% |
| Embecta Corp. | 221.5 Million USD | 170.232% |
| Harrow Health, Inc. | 580 Thousand USD | 26921.207% |
| Procaps Group, S.A. | 38.97 Million USD | 499.156% |
| Biofrontera Inc. | -22.67 Million USD | -585.995% |
| DURECT Corporation | -36.88 Million USD | -321.763% |
| PainReform Ltd. | -9.58 Million USD | -1523.153% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -2852.42% |
| OptiNose, Inc. | -22.74 Million USD | -583.854% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 1331.499% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 1342.02% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -2404.71% |
| ProPhase Labs, Inc. | -21.61 Million USD | -619.766% |
| Phibro Animal Health Corporation | 53.31 Million USD | 391.781% |
| Procaps Group S.A. | 52.32 Million USD | 397.307% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -1725.214% |
| Viatris Inc. | 766.2 Million USD | 120.303% |
| Rockwell Medical, Inc. | -6.67 Million USD | -2232.279% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -2860.849% |
| Tilray Brands, Inc. | -174.74 Million USD | 10.977% |
| PetIQ, Inc. | 60.01 Million USD | 359.207% |
| Talphera, Inc. | -16.88 Million USD | -821.091% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 162.002% |
| Alimera Sciences, Inc. | -1.47 Million USD | -10475.323% |
| Assertio Holdings, Inc. | -243.53 Million USD | 36.123% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -2540.071% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | -12.85% |
| Hempacco Co., Inc. | -8.81 Million USD | -1665.298% |
| Alvotech | -354.86 Million USD | 56.162% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 142.662% |
| Kamada Ltd. | 10.06 Million USD | 1645.737% |
| Currenc Group, Inc. | -6.64 Million USD | -2240.777% |
| Indivior PLC | -4 Million USD | -3789.075% |
| Evoke Pharma, Inc. | -7.43 Million USD | -1993.464% |
| Flora Growth Corp. | -50.35 Million USD | -208.939% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -675.873% |
| Evolus, Inc. | -49.23 Million USD | -215.973% |
| HUTCHMED (China) Limited | 18.37 Million USD | 946.601% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 178.971% |
| Akanda Corp. | -10.05 Million USD | -1447.679% |